Business
IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting
LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an
About this update from Imunon, Inc.
[{"type":"text","content":"LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, FL and virtually. The immunotherapy, IMNN-001 (formerly GEN-1), is currently in Phase 2 development for the localized treatment of advanced ovarian cancer. The abstract is titled “Efficacy of GEN-1, an interleukin-12 immune gene therapy, at different dose frequencies.” Details of the presentation are as follows: Session Category:Clinical Research Excluding TrialsSession Title:Immunomodulatory Agents and InterventionsSession Date and Time:Tuesday, April 18, 2023 (9:00 AM - 12:30 PM)Location:Poster Section 40Poster Board Number:26Published Abstract Number4440Presenter:Jean Boyer, Ph.D., Vice President of Preclinical Research, IMUNON AACR abstracts were published yesterday afternoon and are now available on the AACR website at www.aacr.org. About IMUNON IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON has two platform technologies: the TheraPlas modality for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE modality for the development of nucleic acid vaccines for infectious diseases and cancer. The company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the company is conducting preclinical proof-of-concept studies on a nucleic acid vaccine candidate targeting the SARS-CoV-2 virus to validate its PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems ...